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Abstract
Glycodelin is a major glycoprotein expressed in reproductive tissues, like secretory and decidualized endometrium. It has
several reproduction related functions that are dependent on specific glycosylation, but it has also been found to drive
differentiation of endometrial carcinoma cells toward a less malignant phenotype. Here we aimed to elucidate whether
the glycosylation and function of glycodelin is altered in endometrial carcinoma as compared with a normal endometrium.
We carried out glycan structure analysis of glycodelin expressed in HEC-1B human endometrial carcinoma cells (HEC-1B
Gd) by mass spectrometry glycomics strategies. Glycans of HEC-1B Gd were found to comprise a typical mixture of high-
mannose, hybrid, and complex-type N-glycans, often containing undecorated LacNAc (Galβ1–4GlcNAc) antennae.
However, several differences, as compared with previously reported glycan structures of normal human decidualized
endometrium-derived glycodelin isoform, glycodelin-A (GdA), were also found. These included a lower level of sialylation
and more abundant poly-LacNAc antennae, some of which are fucosylated. This allowed us to select lectins that showed
different binding to these classes of glycodelin. Despite the differences in glycosylation between HEC-1B Gd and GdA, both
showed similar inhibitory activity on trophoblast cell invasion and peripheral blood mononuclear cell proliferation. For the
detection of cancer associated glycodelin, we established a novel in situ proximity-ligation based histochemical staining
method using a specific glycodelin antibody and UEAI lectin. We found that the UEAI reactive glycodelin was abundant in
endometrial carcinoma, but virtually absent in normal endometrial tissue even when glycodelin was strongly expressed. In
conclusion, we established a histochemical staining method for the detection of endometrial carcinoma-associated glycodelin
and showed that this specific glycodelin is exclusively expressed in cancer, not in normal endometrium. Similar methods can
be used for studies of other glycoproteins.
Introduction
Glycodelin (also known as Progestagen Associated Endo-
metrial Protein, PAEP, and Placental Protein 14, PP14) is a
secreted human lipocalin-family protein mainly expressed
in well-differentiated epithelial cells in human reproductive
tissues, like endometrium and seminal vesicles [1, 2]. In
premenopausal endometrium the expression of glycodelin is
temporally regulated by progesterone, expression increasing
shortly after ovulation until the end of the menstrual cycle.
Depending on the cell of origin glycodelin is differently
glycosylated, resulting in glycodelin isoforms with different
biological actions [1, 3–8]. We have previously character-
ized four types of glycodelin, which are derived from dif-
ferent reproductive tissues: decidualized endometrium-
derived glycodelin-A (GdA, isolated from amniotic fluid),
glycodelin-F (isolated from follicular fluid), glycodelin-C
(isolated from cumulus cells), and seminal vesicle-derived
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glycodelin-S (GdS, isolated from seminal plasma)
[5, 7, 9, 10]. Each of these expresses a characteristic glycan
profile. This translates to differences in functional assays.
Thus, while glycodelin-A inhibits sperm–egg binding, i.e.,
fertilization, glycodelin-S prevents premature sperm capa-
citation, but does not prevent sperm–egg binding [10, 11].
In contrast, glycodelin-F prevents premature acrosome
reaction of sperm, whilst glycodelin-C, which is believed to
be derived from glycodelin-F via glycan processing by
cumulus cells, stimulates sperm–egg binding [4, 12, 13].
Thus, it appears that different glycodelin isoforms partici-
pate in a cascade of activities regulating the sperm functions
needed for successful fertilization. Furthermore, immuno-
suppressive activities of glycodelin have been ascribed to
glycosylation [5, 14]. These include the inhibition of per-
ipheral blood mononuclear cell (PBMC) proliferation
[5, 15]. We have previously also reported that glycodelin-A
inhibits trophoblast invasion, while deglycosylated glyco-
delin or differentially glycosylated glycodelin-F does not
have this activity [16]. Tight regulation of trophoblast
invasion is essential for successful pregnancy [17]. Based
on these studies, glycodelin is considered as a remarkable
example of how glycosylation may dictate the functions of
glycoproteins [18].
We have suggested that glycodelin also acts as a tumor
suppressor protein, at least in endometrial carcinoma, based
on our findings showing that glycodelin transfection in
HEC-1B human endometrial carcinoma cells cause mor-
phological reversion from malignant phenotype to a more
normal state [19–21]. This is mediated by a repressed PKC-
δ activation [21]. Furthermore, in a preclinical mouse
model, glycodelin-induced differentiation brought about
reduced tumor growth [20]. Further proof for the inhibitory
role of glycodelin in malignant transformation comes from
the studies in which reversion of Ishikawa endometrial
adenocarcinoma cells to resemble normal endometrial epi-
thelial cells was induced by histone deacetylase inhibitors
[22]. This differentiation was accompanied by glycodelin
synthesis. Importantly, knockdown of glycodelin expres-
sion by RNA-interference blocked the malignant-to-normal
reversion, demonstrating that glycodelin is crucial in this
process. Glycodelin transfection into these cells caused
reduced cell proliferation [23]. Malignant growth is asso-
ciated with loss of cell differentiation, and many tumor
suppressor genes that protect cells against malignant trans-
formation are known to regulate cell differentiation [24].
Therefore it is not surprising that the expression of glyco-
delin is reduced in hormone-related cancers, including
ovarian and breast cancers, and further reduced in less
differentiated tumors [25–27].
Complex glycosylation, which greatly increases the
structural diversity of glycoproteins, is essential for multi-
cellular organisms [28]. Despite the utmost importance of
protein glycosylation, the human glycome is not well
characterized, mainly due to complexity of carbohydrate
structures. Changes in protein glycosylation have been
observed in several human cancers, where they affect
tumorigenic properties, like cellular growth behavior,
invasiveness and acquisition of metastatic potential
[29–32]. Although many glycodelin isoforms have been
characterized from reproductive tissues, nothing is known
about the glycosylation of glycodelin produced by endo-
metrial carcinoma tissue. Here, with the aid of glycomics
analysis, we established a novel glycodelin–glycoform-
specific histochemical staining method and showed that
glycodelin is differentially glycosylated in endometrial
carcinoma tissue as compared with normal endometrium.
Material and methods
Production and purification of glycodelin
HEC-1B cells (ATCC HTB-113), which do not normally
produce glycodelin, were stably transfected with glycodelin
cDNA [20, 21]. This cell line is a subline [33] of HEC-1
cells derived from a moderately differentiated papillary
adenocarcinoma tumor from a patient with stage IA endo-
metrial cancer [34]. The cells were cultured in RPMI-1640
(Lonza), supplemented with 10% fetal calf serum (FCS),
100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM
L-glutamine, at 37 °C in humidified incubator with 5% CO2.
The cell clones were authenticated as HEC-1B cells using
microsatellite markers (Promega GenePrint 10 System) by
the Institute for Molecular Medicine Finland (FIMM)
Technology Centre, University of Helsinki.
Glycodelins from HEC-1B cell culture medium (HEC-
1B Gd) and pooled amniotic fluids (glycodelin-A, GdA)
were purified using a monoclonal anti-glycodelin antibody
(F43-7F9) column as described previously [35]. Before
purification Triton X-100 (0.1% final concentration) was
added to the cell culture medium or amniotic fluid.
After affinity purification, buffer was changed to PBS
and any detached antibodies were removed using
protein G column. Glycodelin preparations were con-
centrated using a centrifugal filter device (Amicon Ultra-4,
10,000 NMWL) and the concentrations were measured by
an immunoassay [36].
Glycomics analysis by MALDI-TOF/TOF and data
interpretation
Glycomics analysis was performed using strategies pre-
viously optimized for GdA characterization [5, 7, 37].
Purified HEC-1B Gd (50 µg) was digested using sequencing
grade trypsin (Promega). The N-glycans were then released
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by N-glycosidase F (Roche Applied Science) and separated
on Sep-Pak C18 cartridges. The native N-glycans were
permethylated using the sodium hydroxide procedure,
subjected to chloroform extraction, and a further clean-up
step using Sep-Pak C18 cartridges. The purified per-
methylated N-glycans were then dissolved in methanol and
an aliquot of the sample was mixed with a 3,4-diamino-
benzophenone matrix solution (10 mg/ml in 75% acetoni-
trile/water) (Acros Organics) at a 1:1 ratio (v/v). The
glycan–matrix mixture was spotted on a MALDI plate and
allowed to dry and crystallize. MALDI-TOF and -TOF/TOF
(MS and MS/MS) data were obtained using a 4800
MALDI-TOF/TOF mass spectrometer (AB Sciex UK
Limited) in positive ion mode. Argon was used as the
collision gas with collision energy of 1 kV.
The MALDI MS and MS/MS data obtained were ana-
lyzed using Data Explorer 4.9 (AB Sciex UK Limited).
Manual assignment of glycan sequences was based on the
known biosynthetic pathways, with the aid of the glyco-
bioinformatics tool, GlycoWorkBench [38].
Lectin immunoassays
Lectin immunoassays were carried out essentially as pre-
viously described [36], using biotinylated lectins obtained
from Vector Laboratories or from Sigma (Table 1). Briefly,
Table 1 Lectin-immunoassay
results.
Lectina Abbreviation Reaction withb Specificityc
GdA HEC-1B Gd
Sambucus nigra SNA +++ − Neu5Acα6Gal/GalNAc
Erythrina cristagalli ECL − +++ Galβ4GlcNAc
Ulex europaeus I UEAI − +++ αFuc
Concanavalin A Con-A + +++ αMan, αGlc
Pisum sativum PSA + + αMan, αGlc
Lens culinaris LCA + +++ αMan, αGlc
Ricinus communis I RCA I + + Gal
Griffonia simplicifolia II GSL II − − αGal
Griffonia simplicifolia I GSL I − − αGal, αGalNAc
Dolichos biflorus DBA − − αGalNAc
Soybean SBA + +++ α > βGalNAc
Sophora japonica SJA − − βGalNAc
Vicia villosa VVA − − GalNAc
Wistera floribunda WFA + ++ GalNAc
Wheat Germ WGA + ++ GlcNAc
Succinylated Wheat Germ WGAsucc + +++ GlcNAc
Datura stramonium DSL − − (GlcNAc)2–4
Lycopersicon esculentumd LEL − − (GlcNAc)2–4
Solanum tuberosum STL + + (GlcNAc)2–4
Peanut PNA − − Galβ3GalNAc
Jacalin Jacalin − − Galβ3GalNAc
Phaseolus vulgaris Erythroagglutinin PHA-E − − Galβ4GlcNAcβ2Manα6
(GlcNAcβ4)
(GlcNAcβ4Manα3)
Manβ4
Phaseolus vulgaris Leucoagglutinin PHA-L + + Galβ4GlcNAcβ6(GlcNAc
β2Manα3)Manα3
aLectin from Wisteria floribunda (WFA, L-1516) was obtained from Sigma. Other lectins were from Vector
Laboratories as Biotinylated Lectin Kits I, II, and III.
b−, no reactivity (signal <1.5-fold of that of blank, i.e., signal obtained with biotinylated lectin and labeled
antibody without GdA or HEC-1B Gd); +, positive signal (>1.5-fold blank); ++, >2- and <4-fold
difference between the reactivity with GdA and HEC-1B Gd (after deduction of blank value); +++, >4-fold
difference between the reactivity with GdA and HEC-1B Gd. The relative reactivity between different lectins
cannot be deduced from the table.
cSpecificity is based on the manufacturer’s (Vector Laboratories) information.
dHigh background signal (perhaps due to direct binding of the detection antibody to the lectin).
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biotinylated lectins were captured on streptavidin coated
wells (96-well plate; PerkinElmer). In the assay, 25 µl
sample (dilutions of HEC-1B Gd and GdA) and 200 µl
assay buffer, supplemented with 1 mM CaCl2, MnCl2, and
MgCl2, were incubated overnight at 4 °C in wells. After
washing the wells Eu-labeled antibody against glycodelin
(F25-9D8) was added for 2 h at room temperature. After
washing enhancement solution was added and the fluores-
cence was measured.
Invasion assays
Human placental tissue was obtained with a written consent
from women who underwent surgical termination of preg-
nancy in the first trimester. Primary trophoblast expressing
CK7 and HLAG were obtained as described [39, 40].
Briefly, the placental villi were digested with trypsin and
DNAase, filtered through 100 and 40 μm filters, and cen-
trifuged by using density gradient media (Ficoll-Paque).
The isolated cells were then incubated in a plastic culture
dish for 20 min to remove adherent leukocytes. Non-
adherent cells were seeded onto fibronectin-coated plates
and incubated overnight.
The adherent primary trophoblasts and JEG-3 human
choriocarcinoma cells (ATCC HTB-36) were cultured in
Dulbecco’s Modified Eagle Medium and Eagle’s Minimum
Essential Medium (EMEM) (Lonza), respectively, supple-
mented with 10% FCS, 100 IU/ml penicillin, 100 µg/ml
streptomycin, and 2 mM L-glutamine, at 37 °C in a humidi-
fied, CO2-controlled (5%) incubator. Primary trophoblasts
(3 × 105) and JEG-3 cells (1.5 × 105) in serum free medium
containing 0 or 10 µg/ml either GdA or HEC-1B Gd were
added into Polycarbonate Membrane Transwell® inserts with
8.0 µm pore size (Corning, Inc.) covered with 100 µl phenol-
red free MatrigelTM Basement Membrane Matrix (BD
Biosciences) diluted 1:2 with EMEM. The inserts were
placed into 24-well plate containing 400 µl of culture med-
ium with 10% FCS and incubated for 22 h. The Matrigel and
the non-invasive cells were removed using cotton swabs and
the membranes were stained with 0.09% crystal violet for
10 min. The cells were counted under a microscope and the
mean of three fields per membrane was calculated.
XTT cell viability assays
Human female peripheral blood was obtained from the
Hong Kong Red Cross. PBMCs were isolated by density
gradient centrifugation (Ficoll-Paque). Cell viability was
determined by the XTT assay (Roche Diagnostics)
according to the manufacturer’s protocol. In brief, PBMCs
(3 × 104) were incubated with 0.01, 0.1, 1, and 10 µg/ml
glycodelins for 36 h, and XTT-labeling mixture was added
12 h before absorbance measurement at 450 and 595 nm.
The cell viability was expressed as relative viability (%)
using the following equation:
Relative viability ð%Þ ¼ ðAbs GdA Abs blankÞ=
ðAbs control Abs blankÞ  100%:
Histochemical stainings
Formalin-fixed, paraffin-embedded tissue samples were
collected at Pathology Department, the Helsinki University
Hospital, Helsinki, Finland. Tissue microarrays (TMA)
including 75 endometrial carcinomas of the endometrioid
subtype and 52 samples of normal control endometrium
were prepared as described previously [41]. The clin-
icopathological data of the patients selected for this study
are shown in Table 2. Three secretory phase endometrium
samples served as positive controls. Approvals of the
Institutional Review Board of the Helsinki University
Hospital and the National Supervisory Authority for Wel-
fare and Health were obtained.
Five µm thick sections were cut from the tissue and TMA
blocks and placed onto glass slides. For histochemical
stainings (below), the sections were deparaffinized and
rehydrated. Stainings were scored by an experienced
pathologist (A.P.).
Glycodelin staining
To enhance the antigen retrieval the sections were heated in
citrate buffer (pH 6.0) in a microwave oven for 10 min. This
was followed by the addition of peroxidase-blocking solu-
tion (Dako REAL, #S2023, DAKO) for 30 min and horse
serum (diluted 1:20 in PBS, Vector Laboratories) for
20 min, both at room temperature. Rabbit (#1) anti-
glycodelin IgG [25] was used as the primary antibody
(3 µg/ml, incubated for overnight at +4 °C) and the IgG
fraction from preimmune serum of the same rabbit (3 µg/ml)
was used as a negative control. Labeled polymer-HRP anti-
rabbit (DAKO, K4009) was used as a secondary detection
reagent (30 min at room temperature). Histofine Simple
Stain AEC Solution (Nicherei Biosciences) was used as a
chromogen for antigen detection. Counterstaining was
performed with modified Mayer’s staining solution
(#01820, Histolab Products Ab). For the progesterone
receptor (PR) staining, 3 µm sections were stained with
Ventana Benchmark Ultra (Roche/Ventana). Heat-induced
epitope retrieval was performed using standard pretreatment
buffer CC1 (Roche/Ventana), 64 min/98 °C. The slides
were incubated with PR antibody (dilution 1:50, clone 16,
NCL-L-PGR-312, Novocastra) 32 min/37 °C. For detection
we used multimer-based detection kit Optiview (760-700,
Roche/Ventana). The slides were counterstained with
Mayer’s hematoxylin, and were then dehydrated and
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mounted for viewing with microscope. Glycodelin staining
was scored either strong positive, weak/focal positive, or
negative. PR staining was scored either positive or negative.
Glycodelin–UEAI-lectin in situ proximity ligation
assay (PLA®)
Unless otherwise indicated, in situ PLA® was performed
using the Duolink® reagents essentially according to man-
ufacturer’s instructions (Sigma-Aldrich). Briefly, endogen-
ous peroxidase activity was blocked by 30 min treatment
with 0.3% H2O2 (DUO82054) at room temperature. Tissue
slices were blocked using blocking solution (DUO82007)
for 30 min at 37 °C. Monoclonal mouse antibody against
glycodelin [3 µg/ml, F25-9D8 [36]] and biotinylated Ulex
europaeus agglutinin I (UEAI) (5 µg/ml, Vector Labora-
tories) were diluted in antibody diluent (DUO82008) and
incubated with sections overnight at 37 °C. Duolink in situ
PLA Probe Anti-Mouse PLUS (DUO92001) and strepta-
vidin (2 µg/ml) conjugated with Duolink In Situ probemaker
MINUS (DUO92010) were used as detection probes. The
reaction with probes, ligation, amplification (2 h at 37 °C),
and detection were performed according to the manu-
facturer’s instructions. The luminal and cytoplasmic stain-
ing were scored either positive or negative.
Lectin staining
Endogenous peroxidase activity was blocked using
peroxidase-blocking solution (Dako REAL, #S2023) for 30
min, followed by incubation with horse serum (diluted 1:20
in PBS, Vector Laboratories) for 20 min, both at room
temperature. Biotinylated UEAI lectin (25 µl/ml in PBS
containing 1% BSA, 1 mM CaCl2, 1 mM MgCl2, 1 mM
MnCl2) was incubated overnight at +4 °C. ABC kit (PK-
6100, Vector Laboratories) was used as a secondary
detection reagent according to manufacturer’s instructions.
Staining with AEC and Mayer’s staining solution were
performed as in glycodelin staining. Staining in carcinoma
cells and epithelial cells of normal endometrium was scored
either positive or negative (<10% of cells stained). Blood
vessels were not included in the evaluation.
Data analyses
Fisher’s exact test (two-sided, IBM SPSS Statistics 24) was
used to evaluate associations between different patient
groups and staining. T-test (two-sample unequal variance,
two-sided, Microsoft Excel) was used to evaluate differ-
ences in biological activity of different glycodelin
preparations.
Results
Glycomics analysis of glycodelin expressed by
HEC-1B cells (HEC-1B Gd)
Glycomics analysis was performed using strategies pre-
viously optimized for GdA characterization [5, 7]. The
permethylated N-glycans were subjected to MALDI-MS
profiling and MALDI-MS/MS sequencing. The complete
MALDI-MS spectrum of the N-glycans of HEC-1B Gd and
annotation of the most abundant informative molecular ions
is shown in Fig. 1a. Comprehensive annotations are shown
on the magnified spectrum in Supplementary Fig. The
glycan structures were manually assigned by combining
Table 2 Clinicopathological data in relation to glycodelin (Gd), UEAI
lectin (UEAI) and UEAI-glycodelin (UEAI-Gd) staining.
n (%)b Gd pos.
n (%)c
UEAI pos.
n (%)c,d
UEAI-Gd
pos n (%)c
Endometrial
carcinomaa
75 (100) 22 (29) 57 (77) 36 (48)
Grade
1–2 65 (87) 21 (32) 51 (78) 33 (51)
3 10 (13) 1 (10) 6 (67) 3 (30)
p valuee p= 0.26 p= 0.42 p= 0.31
Stage
I 62 (83) 18 (29) 48 (79) 29 (47)
II–IV 13 (17) 4 (31) 9 (69) 7 (54)
p valuee p= 1.0 p= 0.48 p= 0.76
Tumor sizef
Diameter < 2 cm 22 (30) 7 (32) 16 (73) 11 (50)
Diameter ≥ 2 cm 51 (70) 14 (27) 39 (78) 24 (47)
p valuee p= 0.70 p= 0.49 p= 0.69
LVIf
Yes 17 (24) 6 (35) 12 (71) 7 (41)
No 55 (76) 15 (27) 43 (80) 27 (49)
p valuee p= 0.80 p= 0.86 p= 1.0
Normal
endometriuma
52 (100) 6 (12) 17 (34) 1 (2)
p value (cancer
vs normal)e
p= 0.018 p < 0.0001 p < 0.0001
aThe mean ± SD age of patients was 65.7 ± 11.3 years (range 37–92
years) and for controls 57.9 ± 6.9 years (range 38–77).
bNumber of samples in each category and in parenthesis percent.
cNumber and in parenthesis percent of positively stained samples in
each category.
dIn UEAI staining one endometrioid carcinoma (grade 3, stage I,
diameter ≥ 2 cm and no LVI) and two control samples were missing.
ep values (Fisher’s exact test, two-sided) between frequency of
positively stained samples in different subgroups or between
carcinoma and normal endometrium.
fTumor size or lymphovascular invasion (LVI) were not available from
2 or 3 patients, respectively.
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information on the N-glycan compositions and knowledge
of human N-glycan biosynthetic pathways. These assign-
ments were then further confirmed and/or corrected based
on MS/MS data, which were also manually interpreted. For
practical reasons not all molecular ions in the spectra could
be sequenced by MALDI-TOF/TOF MS/MS. Nonetheless it
was possible to sequence representative members of each
family of glycans as well as molecular ions not previously
reported in GdA. Molecular ions selected for MS/MS are
indicated with boxed m/z values in Supplementary Fig.
Overall, the HEC-1B Gd glycan population comprised of
a mixture of high-mannose, hybrid, truncated, and abundant
complex N-glycans that is typical of other female
glycodelins (Fig. 1a). The most abundant (in terms of
relative abundance) complex N-glycans corresponded
mainly to core-fucosylated structures with undecorated
Galβ1–4GlcNAc (LacNAc) units on their antennae
(m/z 2244, 2693, 3142, 3591, and 4041). N-glycans with
undecorated GalNAcβ1–4GlcNAc (LacdiNAc) units, also
mainly core-fucosylated, were also detected (m/z 2285,
2326 and 2734), but in minor abundance. Both the LacNAc
and LacdiNAc containing N-glycans were occasionally
decorated by NeuAc (m/z 2605, 2966, 3007, 3415, 4226,
and 4587) or fucose (m/z 2244, 2285, 2326, 2605, 3316,
and 4215) residues. Comprehensive analysis of the mole-
cular ions, the composition of which corresponded to
multiples of LacNAc units (e.g., m/z 3142, 3316, 3415,
3591, 4041, and 4215), indicated that they were actually a
Fig. 1 Glycomics analysis of glycodelin expressed by HEC-1B cells
(HEC-1B Gd). a MALDI-TOF mass spectra of permethylated N-
glycans from HEC-1B Gd. “new” above particular structure, or next to
a m/z value, indicates new structure or a set of structures when com-
pared with the N-glycome of GdA analyzed before [5]. All signals
observed are singly charged sodiated ions [M+Na]+, and their
structural assignment is based on monosaccharide composition, MS/
MS fragmentation analyses (boxed m/z values) and knowledge of the
glycan biosynthetic pathways. Fully annotated spectra that have been
expanded on the m/z axis to enable all components to be visualized, are
presented in Supplementary Fig. Sugars shown on top of a bracket
have not had their antenna location unequivocally defined. For
simplicity, one branching pattern for tri-antennary structures is shown.
Therefore, the position of an antenna in a cartoon does not imply
designation of a specific arm. “M”, “m” and “vm” designations indi-
cate major, minor and very minor abundances, respectively.
b, c Evidence for LacNAc extension of N-glycans. MALDI-TOF/TOF
MS/MS of the molecular ion at (b) m/z 3591 and (c) 4215 as detected
on the MALDI-TOF MS spectrum (see a). The fragment ions are
consistent with the sequences shown in corresponding insets (major
abundance structures). The horizontal arrows on the spectra indicate
losses of glycan moieties from the molecular ion. c The fucose resi-
dues outside the bracket have not had their location unequivocally
defined.
Altered glycosylation of glycodelin in endometrial carcinoma 1019
mixture of isomers of which a minority contained linear
poly-LacNAc antennae. Two examples are the structures
detected for the molecular ions at m/z 3591 and 4215.
MALDI-TOF/TOF MS/MS of the former molecular ion
exhibited fragment ions that corresponded to losses of two
and three LacNAc repeating units (m/z 2679 and 2230,
respectively, Fig. 1b) indicating the presence of linear poly-
LacNAc units. Similarly, the molecular ion at the m/z 4215
exhibited fragment ions that corresponded to losses of two
and three LacNAc repeating units, each further modified
with a fucose residue (m/z 3128 and 2679, respectively,
Fig. 1c). The detection of the fragment ions at m/z 433 and
660, indicated that in certain cases the fucose residue was at
the non-reducing terminus of the above poly-LacNAc units.
Particularly, the presence of fragment ion at m/z 433,
together with the absence of a fragment ion at m/z 834
(indicating the absence of Leb/y epitopes for the specific
molecular ion), suggested the presence of H type antigen
(Fucα1–2Galβ1–3/4GlcNAcβ).
As compared with previously reported N-glycans of GdA
[5, 7], the above N-glycan population of HEC-1B Gd
exhibited differences with the most noticeable being the
following: (i) the reduced abundance of Sda (NeuAcα2-3
[GalNAcβ1-4]Gal) epitope (detected only at m/z 2646,
Supplementary Fig.); (ii) the reduced abundance of sialy-
lated N-glycans; and (iii) the increased abundance of linear
poly-LacNAc units that were further modified with NeuAc
or fucose residues.
Reactivity with lectins
The glycan-analyses data allowed us to select lectins that
potentially show differential binding to GdA and HEC-1B
Gd. Also, several other lectins were tested (Table 1). The
lecting binding studies confirmed the differences between
the glycans of HEC-1B Gd and GdA. We found that UEAI
and Erythrina cristagalli agglutinin (ECL) exclusively
recognized HEC-1B Gd, not GdA, while Sambucus nigra
agglutinin (SNA) recognized only GdA. Several other lec-
tins bound preferentially to HEC-1B Gd but bound weakly
also to GdA.
Bioactivity of HEC-1B Gd
The bioactivity of HEC-1B Gd was studied by assays in
which we previously have found glycosylation to be
important for the activity of glycodelin [5, 7, 16]. Tropho-
blast invasion assays were conducted both using primary
trophoblast cells and JEG-3 choriocarcinoma cells. Irre-
spective of the differential glycosylation of HEC-1B Gd and
GdA, these glycodelin isoforms had similar inhibitory
activity on trophoblast cell invasion (Fig. 2a). The same was
observed in inhibition of PBMC viability (Fig. 2b).
Histochemical staining of glycodelin and its UEAI
reactive glycoform in endometrial carcinoma tissue
To test whether the differences found in endometrial car-
cinoma cell line (HEC-1B Gd) and endometrium (GdA)
derived glycodelins are also found in endometrium tissue of
cancer patients and controls, we established a specific
staining method for UEAI lectin-reactive glycodelin
(UEAI–glycodelin).
First, we stained glycodelin with an antibody that does
not discriminate between the glycoforms. In TMA, the
amount of samples with strong glycodelin staining was not
different between the endometrial carcinoma (5.3%) and
control groups (5.8%) (p= 1.0, Fisher’s exact test), while
the overall glycodelin staining (i.e., both strong and weak
focal staining) was more frequent in carcinoma group
(29.3% vs. 11.5%, p= 0.018) (Fig. 3, Table 2). In histo-
logically normal endometrium, glycodelin staining was
found in glandular epithelium, while in tumoral tissue
glycodelin was localized in the carcinoma cells (Fig. 3a–d,
g). However, even the strong staining in the carcinoma
samples tended to be weaker and more focal than that in
non-malignant endometrial tissue, including three histolo-
gical sections of the secretory phase endometrium, which
showed very strong glycodelin staining (Fig. 3a). Interest-
ingly, three endometrial samples in which areas of both
cancerous and histologically normal endometrium were
present showed strong glycodelin staining only in non-
malignant area, while cancerous regions in the same
Fig. 2 Biological activity of
HEC-1B Gd and GdA.
a Trophoblast invasion assays
were performed using primary
trophoblasts (n= 3) and JEG-3
choriocarcinoma cells (n= 6).
b Peripheral blood mononuclear
cell (PBMC) viability was
evaluated by XTT assay (n= 4).
*p < 0.05 or **p < 0.01 vs.
control (T-test). Data represent
mean ± SE.
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sections were glycodelin negative or only weakly stained
(Fig. 3a–c).
In in situ proximity ligation based staining of UEAI
lectin-reactive glycodelin (UEAI–glycodelin) 30.7% of the
endometrioid carcinoma tissues showed luminal staining,
1.3% cytoplasmic staining, and 16.0% both cytoplasmic
and luminal staining (Fig. 3e, h, Table 2). The non-
cancerous tissues showed positive staining only in one case
(p < 0.001 between endometrioid carcinoma and control
samples).
When the tissue sections were stained with UEAI lectin
alone, blood vessels were found to be strongly positive both
in normal and cancerous tissues, while epithelial cells were
more often positive in cancer samples (Fig. 3f, i). The
staining in cancer was also stronger and more often found in
cytoplasm. All the UEAI–glycodelin positive cancer sam-
ples were also UEAI-staining positive.
Almost all (86.5%) carcinoma samples were PR posi-
tive and the frequency of PR positive samples was similar
irrespective of whether the samples were glycodelin or
UEAI–glycodelin positive or negative (p > 0.26 for both).
In the endometrioid carcinoma samples, frequencies of
glycodelin, UEAI–glycodelin, and UEAI-staining positive
samples were not statistically different between low
(grades 1 and 2) and high (grade 3) grade endometrioid
tumors (Table 2). Likewise, no differences in the
frequency of positively-stained samples were found
between small (tumor diameter < 2 cm) and large tumors
(diameter ≥ 2 cm) or whether lymphovascular invasion
was observed (for all p > 0.49). Local carcinomas (stage I)
were not different, in respect of staining frequencies,
from those showing spread beyond the uterine corpus
(stages II–IV).
Discussion
Glycodelin represents one of the foremost examples on how
glycosylation dictates the function of a glycoprotein
[1, 2, 8, 10, 18]. Although protein glycosylation is often
altered in cancer [29–32] nothing is known about the gly-
cosylation of glycodelin in endometrial carcinoma. Here,
we describe a novel method for histochemical staining of a
specific glycodelin–glycoform, based on in situ proximity
ligation with a lectin and antibody. With this method we
showed that glycodelin is differentially glycosylated in
Fig. 3 Histochemical staining of glycodelin, UEAI lectin–reactive
glycodelin (UEAI–glycodelin) and UEAI–binding glycans in nor-
mal endometrium and endometrial carcinoma tissues. Example of
glycodelin staining in a whole tissue section (b), which has both
cancerous region (c) and normal secretory endometrium (a). Insert in
a is a negative control in which the glycodelin antibody has been
replaced with preimmune IgG. Representative examples of strong
glycodelin staining (with antibody) (d, g), UEAI–glycodelin staining
(proximity-ligation based detection with glycodelin antibody and
UEAI lectin) (e, h) and staining of UEAI lectin-reactive glycans
(UEAI lectin staining) (f, i) in normal endometrium (d–f) and endo-
metrial carcinoma (g–i) TMA samples. Scale in a is 100 µm and the
same scale applies to c–i. Scale in b is 200 µm.
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endometrial carcinoma, as compared with normal
endometrium.
In order to establish a specific histochemical staining
method for glycodelin expressed in endometrial carcinoma,
we first carried out glycomics analysis of glycodelin
expressed in the human endometrial carcinoma cell line
HEC-1B. Our aim was to ascertain how the glycomic pro-
files differed from those reported for first trimester GdA and
to use that information to support the selection of lectins for
further studies. To this end, glycomics analysis showed that
the major N-glycans of HEC-1B Gd exhibited decreased
abundance of sialic acid (NeuAc) residues and carried only
very low levels of Sda containing glycans (none in the high-
mass region), abundantly expressed in GdA, especially on
larger glycans [7]. On the contrary, HEC-1B Gd N-glycans
exhibited increased abundance of linear poly-LacNAc units
(two or three LacNAcs) on their antennae, which were
mainly undecorated, or to a lesser extent further modified by
a NeuAc or fucose residue. This is further supported by the
report showing that β1–4-galactosyltransferase, which is
involved in poly-LacNAc synthesis, is increased in endo-
metrial cancer [42]. These differences are not likely to be
explained by variations observed in GdA preparations iso-
lated from endometrium and amniotic fluid of different
individuals and during different times of pregnancy [43].
Next, we tested lectins that, based on the above gly-
comics analysis, were predicted to differentiate between
carcinoma associated HEC-1B Gd and normal endometrium
GdA. Decreased sialylation of HEC-1B Gd as compared
with GdA suggested that SNA may differentiate between
these two glycodelins and, indeed, SNA did not bind to
HEC-1B Gd, while strong reaction with GdA was observed.
Similarly, more abundant LacNAc epitopes in HEC-1B Gd
agreed with increased ECL binding. However, it was
somewhat surprising that LEL, DSL, and STL lectins,
which should also bind poly-LacNAc [44], did not react
well with HEC-1B Gd or GdA. Negative results are not
necessarily informative as they may reflect low-binding
affinity of the lectin in the assay conditions, rather than
indicate genuine lack of the given carbohydrate epitope.
Moreover, as the lectin binding was determined with a
sandwich type of an assay, using glycodelin-specific
monoclonal antibody and lectins, we could not rule out
possible sterical hindrance preventing the binding of both
the antibody and some of the lectins.
UEAI, a lectin that has been found to strongly recognize
H type epitopes [45, 46], was found to bind well HEC-1B
Gd. Indeed, MALDI-TOF/TOF MS/MS analysis showed a
minor marker fragment ion corresponding to a fucose
residue attached to a terminal galactose residue (m/z 433,
Fig. 1c), suggesting the presence of H type antigen on
elongated LacNAc antennae on the HEC-1B Gd. UEAI
lectin also reacts with other fucosylated epitopes, such as
Ley and Lex epitopes [45–47]. However, UEAI did not
show any significant binding to GdA. Since GdA exhibits
Lex antigens [9], binding to it should have been expected to
some extent [5, 7, 9]. As fucosylated glycans in GdA are
more prevalent in the Asn-63 glycosylation site [9], it is
possible that the binding of UEAI to this glycosylation site
could be blocked by the antibody binding in close
proximity.
We have previously characterized several glycodelin
isoforms, which differ especially in the level of sialylation
and abundance of glycans with Sda epitopes [5, 7, 9], and
have different effects on the viability of PBMCs. This may
be due to reduced sialic acid content, as desialylation of
GdA was found to abolish the immunomodulatory activity.
Thus, it was somewhat surprising that HEC-1B Gd, which
also appears to contain less sialic acids than GdA, had
inhibitory activity on PBMC viability similar to GdA.
However, as several different glycans in GdA are sialylated,
it is possible that only some of those, which are also present
in HEC-1B Gd, mediate the antiproliferative effect of gly-
codelin on PBMC or that different glycans can produce
similar effect. Using enzymatic deglycosylation and/or
differentially glycosylated glycodelin isoforms, we have
found, that in addition to PBMC proliferation, the inhibitory
activity of GdA on trophoblast invasion is dependent on
glycosylation [16]. Again, despite the differences in gly-
cosylation between GdA and HEC-1B Gd, both of these
glycodelin glycoforms inhibited trophoblast invasion in
similar potency.
After establishing, by glycan-analyses and lectin-binding
studies, that HEC-1B endometrial carcinoma cells produce
glycodelin with different N-glycans than normal endome-
trium, we studied whether this can be seen also in endo-
metrial carcinoma tissues. This is feasible as glycosylation
of endometrial proteins is not only dependent on the phase
of the menstrual cycle and menopausal status, but is further
changed in malignant endometrium [48]. First, we studied
glycodelin expression in normal endometrium and endo-
metrial carcinoma. Previous studies have shown that high
glycodelin expression is restricted to secretory endome-
trium, while expression in proliferative phase or post-
menopausal endometrium is very low if detectable at all [1].
In order to detect also low levels of glycodelin, we used
high antibody concentration, which stained normal secre-
tory endometrium very strongly. Immunoreactive glycode-
lin was not often found in TMA samples, mostly obtained
from postmenopausal women, and, apart from the few TMA
samples representing normal secretory endometrium, the
staining was weaker than that observed in control histolo-
gical sections of normal secretory endometrium. Relatively
strong glycodelin immunoreactivity was found in some
samples, but there was no difference in frequencies of such
samples between normal and endometrioid carcinoma
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groups. However, weak and focal glycodelin staining was
observed more frequently in carcinoma samples. Interest-
ingly, in few carcinoma samples containing adjacent his-
tologically normal secretory epithelium, strong staining was
observed only in the latter, suggesting that glycodelin
expression may be reduced during malignant transforma-
tion. Previously most studies have not found glycodelin in
cancerous endometrium [1]. One group has reported fre-
quent glycodelin staining in endometrial cancer, which
appears to be somewhat dependent on the used antibody
[49]. Of note, glycodelin transcripts (mRNA) are more
abundant in normal uterus than in uterine carcinomas [IST
Online® ver. 2.1.3 database, containing gene expression
data of about 20,000 samples, http://ist.medisapiens.com/
[50]]. Glycodelin is also expressed in ovarian and breast
cancers, where the levels are reduced in less differentiated
tumors [25–27].
We found more frequent and stronger UEAI staining in
endometrial cancer than in normal endometrium. Previous
lectin studies have also shown that the binding of UEAI and
its glycan epitope, H type antigen, are increased in endo-
metrial carcinoma [51–53]. This corroborates with other
reports showing that in endometrial carcinoma there is an
increased expression of fucosyltransferases responsible for
the expression of fucosylated epitopes including H type
antigen [54, 55]. Also, lectin histochemistry on breast
cancer tissues has shown a major reduction of UEAI
staining after endo-β-galactosidase digestion, suggesting
that UEAI lectin on breast cancer tissues recognizes fuco-
sylated antigens on elongated LacNAc antennae of
N-glycans [56].
As the UEAI lectin binds HEC-1B Gd, but not GdA, and
UEAI staining was stronger in endometrium carcinoma than
in normal tissue, we next studied whether the specific UEAI
reactive glycodelin (UEAI–glycodelin) would be more
abundant in endometrial carcinoma than in normal endo-
metrium. To this end, we established an in situ proximity
ligation assay [57] with a combination of glycodelin anti-
body and UEAI lectin. A similar combination of an anti-
body and a lectin has previously been used for proximity-
ligation assay for serum and tissue lysate samples [58] and
an in situ approach has been used with a combination of
protein- and glycan-specific antibodies [59, 60]. However,
to our knowledge this is the first report for such a protein-
glycoform-specific histochemical staining with a lectin-
antibody combination.
UEAI–glycodelin staining was almost exclusively found
in endometrial carcinoma tissues and it was more frequent
than the glycodelin staining. This is in keeping with the
strong binding of UEAI to HEC-1B Gd, while no significant
binding to GdA was observed. The staining was mostly
found in luminal part, which suggests that the UEAI reac-
tive glycans are mature only at the late stage of the secretory
pathway. As proximity-ligation is a very sensitive techni-
que, all glycodelin positive samples would have been
expected to be positive also in UEAI–glycodelin staining.
However, this was not the case. Thus, it is possible that in
carcinoma samples glycodelin does not always carry UEAI
reactive glycans. It has to be also noted that the tissue cores
in TMA were quite small and the stained sections were not
consecutive. Therefore, the pairwise comparison may not
tell the whole truth. The lack of the glycodelin staining in
some of the UEAI–glycodelin positive samples may be
related to the same fact and a less sensitive method. Another
possibility is the lack of specificity in the UEAI–glycodelin
staining. However, this is unlikely as staining was absent
both in blood vessels showing very strong UEAI reactivity
(but no glycodelin staining) and in normal secretory endo-
metrium samples containing high level of glycodelin.
The staining of UEAI–glycodelin appeared not to be rela-
ted to tumor aggressiveness because significant associations
with grade, stage, size, or lymphovascular invasion were not
observed. An earlier study has shown that glycodelin levels
are elevated in plasma and uterine flushings in post-
menopausal women with endometrial adenocarcinoma, as
compared with those without neoplasia [61]. Since UEAI-
reactive glycodelin was found, with one exception, only in
carcinoma samples, it is likely that its circulating levels would
be more specific for detection of endometrial cancer than those
of total glycodelin. However, whether UEAI–glycodelin, as an
apparent neoantigen in endometrial carcinoma, is a suitable
marker for cancer detection, or target for vaccination strategies
[62] or cancer treatment, remains to be studied.
In conclusion, using mass spectrometry glycomics stra-
tegies and lectins, we found that glycodelin expressed in
HEC-1B human endometrial carcinoma cell line is differ-
entially glycosylated as compared with normal decidualized
endometrium-derived glycodelin. Despite of the differences
in glycosylation these glycodelin isoforms had similar
inhibitory activity on trophoblast cell invasion and PBMC
proliferation, activities that we have previously found to be
associated with specific glycosylation of glycodelin. We,
furthermore, established a novel in situ proximity ligation
assay with a lectin and an antibody, and showed that gly-
codelin is differentially glycosylated in endometrial carci-
noma tissues as compared with normal endometrium.
Whether specific detection of such glycodelin in endo-
metrial carcinoma has any clinical significance remains to
be established. Similar approach and methods can be used
for studies of other glycoproteins.
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